Dr. Sartor shares phase 3 trial data on 117Lu-PSMA-617 in mCRPC

News
Video

"The surprise to me was the grade 3/4 adverse events [were] better with 177Lu-PSMA-617, SAEs [were] better with 177Lu-PSMA-617, and dose adjustments [were] better with 177Lu-PSMA-617," says Oliver Sartor, MD.

In this video, Oliver Sartor, MD, highlights findings from the phase 3 PSMAfore (NCT04689828) trial exploring 177Lu-PSMA-617 in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), which he presented at the 2023 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain. Sartor is the director of radiopharmaceutical trial at Mayo Clinic in Rochester, Minnesota.

Video Transcript:

The primary end point of rPFS was met in a primary analysis, the hazard ratio 0.41. We had a secondary analysis presented here; hazard ratio is 0.43, essentially the same. Confidence intervals were small, did not overlap 1. If we want to look at the quantitative estimates, the medians were about 12.02 months for the 177Lu-PSMA-617, 5.59 months for the secondary hormone. Again, those are significant differences, more than doubling in the rPFS.

Then, of course, we had a whole variety of secondary end points. Among the secondary end points was a crossover adjusted overall survival (OS). That came out at a hazard ratio 0.8. Those confidence intervals are still pretty big; they did overlap 1. So, not a statistically significant crossover adjusted OS. Then we looked at a whole bunch of other things like health-related quality of life –that was better with 177Lu-PSMA-617. We looked at time to PSA, time to pain progression – that was better with 177Lu-PSMA-617. We looked at PSA decline rates – that was better with 177Lu-PSMA-617. Objective responses were better with 177Lu-PSMA-617. [We] looked at the symptomatic skeletal events – that was better with 177Lu-PSMA-617. And [we] looked at adverse events, and adverse events were better with 177Lu-PSMA-617. So, we had a whole litany of end points that are positive with lutetium, as compared to secondary hormones. The surprise to me was the grade 3/4 adverse events better with 177Lu-PSMA-617, SAEs better with 177Lu-PSMA-617, and dose adjustments [were] better with 177Lu-PSMA-617. So, the hormones were adjusted in dose about 50% of the time, and 177Lu-PSMA-617 was only about a third of that. That was surprising. Discontinuation rates [were] small, about 5% in each arm.

This transcription has been edited for clarity.

Recent Videos
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Quitting smoking - male hand crushing cigarette | Image Credit: © mbruxelle - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Elisabeth M. Sebesta, MD, answers a question during a Zoom video interview
Katherine Chan, MD, MPH, answers a question during a Zoom virtual interview
Adity Dutta, MSN, AGACNP-BC, gives an answer during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.